Physician profile
Peter Yoo
NPI 1720022205
$2,068.71
in general payments reported to CMS, 2019-2025
15 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $197 · 2021: $61.54 · 2022: $16.34 · 2023: $345 · 2024: $508 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $699.02 | 2019-2025 | Watchman Flx, Eluvia, Watchman Access System |
| Medtronic, INC. | $290.93 | 2023-2025 | Venaseal, Endo Gia Ultra, Linq II |
| Novartis Pharmaceuticals Corporation | $247.65 | 2019-2025 | |
| Edwards Lifesciences Corporation | $138.50 | 2024-2025 | Pascal, Evoque |
| E.R. Squibb & Sons, L.L.C. | $110.18 | 2019-2024 | |
| Amgen INC. | $99.83 | 2019-2025 | |
| Pfizer INC. | $98.13 | 2019-2025 | |
| Abbott Laboratories | $94.70 | 2023 | Cardiomems |
| Abiomed | $90.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $88.56 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.44 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.92 | 2019-2024 | Jardiance |
| Angiodynamics, INC. | $22.95 | 2024 | Venacure 1470 Pro |
| Amarin Pharma, INC. | $16.82 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $13.47 | 2025 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.